Established in 2014, C60 Pan Asia Limited has grown from strength to strength as a leader in delivering innovative medical technology and laboratory solutions across Hong Kong and Asia over the last 10 years.

With a strong commitment to quality, the company provides healthcare professionals with cutting-edge tools designed to enhance diagnostic accuracy and improve patient care. Their latest development, the Thyroid Genetic Test, is a prime example of how C60 Pan Asia Limited advances healthcare through precision diagnostics and personalized medicine.

Jake Law, Product Manager and Founder of C60 Pan Asia Limited

“The ThyroidPrint® Genetic Test represents our dedication to innovation and precision in diagnostics. Thyroid disorders, such as hypothyroidism, hyperthyroidism, and thyroid cancer, are common yet often difficult to diagnose due to their wide range of symptoms. Traditional diagnostic methods, such as hormone blood tests and imaging, offer valuable information but can sometimes miss the underlying genetic causes of these conditions. Our test provides healthcare providers with a deeper, more precise look at the gene expression profile by RT-qPCR Technology, helping to uncover causes that might be missed by conventional methods,” explains Mr. Jake Law, Product Manager and Founder of C60 Pan Asia Limited.
ThyroidPrint® Genetic Test is an RNA-Based signature (10 genes) to help identify patients with indeterminate thyroid nodules that can safely avoid unnecessary thyroid surgery. This test offers a more accurate and sensitive approach than traditional methods, detecting even subtle genetic mutations that may go unnoticed by standard blood tests or imaging. This prevents exposing patients to surgical risks and permanent thyroid hormone supplementation.By providing a genetic-level analysis, the test enables healthcare providers to diagnose thyroid conditions earlier and more precisely. It is particularly valuable for patients with indeterminate results of Thyroid Nodules which might be suspicious as thyroid cancer, those with inconclusive results from traditional tests, or individuals with recurring or complex thyroid issues. By identifying these genetic mutations early, doctors can develop personalized treatment plans, leading to more effective medical approaches.
The test is designed to analyse Fine Needle Aspiration (FNA) Samples from Thyroid Nodules within 3 hours. This rapid turnaround time for results allows healthcare providers to make informed clinical decisions quickly, improving the overall patient experience. “We believe that by offering personalized, genetic-level insights, we can revolutionize the way thyroid disorders are diagnosed and treated, giving healthcare providers the tools they need to make more informed decisions,” says Mr. LawWhile the ThyroidPrint® Genetic Test is a breakthrough in thyroid nodule management, it is just one part of C60 Pan Asia’s broader vision of advancing healthcare. Since its inception, the company has built a reputation for delivering high-quality solutions across various medical fields, including anatomical pathology, molecular pathology, and pharmaceutical products. Their partnerships with globally recognized manufacturers, such as Sakura Fintech Japan Co., Ltd and Biocartis NV, ensure that they continue to provide healthcare professionals with cutting-edge tools and reliable products. C60 Pan Asia Limited’s commitment to quality is reflected in its ISO 9001 and ISO 13485 certifications, which guarantee that all its products meet the highest standards of safety and performance. This dedication extends across their entire product range, from diagnostic tools like the ThyroidPrint®Genetic Test to everyday laboratory consumables that are essential for the smooth operation of healthcare facilities.
Their continued focus on high-quality products and customer satisfaction ensures they remain at the forefront of the medical field, delivering solutions that meet the needs of today’s healthcare challenges and tomorrow’s innovations. The Mediazone Group congratulates C60 Pan Asia Limited for winning the Hong Kong’s Most Valuable Companies 2025 Award. We look forward to seeing the company’s growth and influence in the global healthcare industry. For more information see the video below or visit www.c60panasia.com